Literature DB >> 17126678

Molecular basis of differences among statins and a comparison with antioxidant vitamins.

R Preston Mason1.   

Abstract

Although all statin drugs lower levels of circulating low-density lipoprotein cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A, molecular differences among statins affect their metabolism, solubility, and intramembrane localization, which in turn is likely to influence their efficacy and safety. In addition, these properties may have a differential impact on the pleiotropic effects of statins, including their ability to improve endothelial function and to affect proliferation and apoptosis in vascular tissues. Many pleiotropic effects of statins appear to be due to inhibition of small guanosine triphosphate-binding proteins and/or restoration of nitric oxide bioavailability, and atorvastatin metabolites may also directly protect vascular tissues from oxidative damage. The possibility of cardiovascular benefits from antioxidant effects of atorvastatin metabolites contrasts with the lack of benefits seen in most studies of antioxidant vitamins. This article reviews some of the differences in pleiotropic effects of statins and assesses the contribution of their solubility and membrane localization as the possible basis for these differences. In addition, the possibility that statin benefits on stroke reflect pleiotropic effects is reviewed. Finally, possible reasons for differences between the effects of atorvastatin metabolites and antioxidant vitamins are considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126678     DOI: 10.1016/j.amjcard.2006.09.018

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Rewiring Host Lipid Metabolism by Large Viruses Determines the Fate of Emiliania huxleyi, a Bloom-Forming Alga in the Ocean.

Authors:  Shilo Rosenwasser; Michaela A Mausz; Daniella Schatz; Uri Sheyn; Sergey Malitsky; Asaph Aharoni; Eyal Weinstock; Oren Tzfadia; Shifra Ben-Dor; Ester Feldmesser; Georg Pohnert; Assaf Vardi
Journal:  Plant Cell       Date:  2014-06-10       Impact factor: 11.277

Review 2.  Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?

Authors:  Jacqueline P Williams; Carl J Johnston; Jacob N Finkelstein
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

3.  Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.

Authors:  Ross J Simpson; James Signorovitch; Howard Birnbaum; Jasmina Ivanova; Cristina Connolly; Yohanne Kidolezi; Andreas Kuznik
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

4.  Reversal of voltage-dependent erectile responses in the Zucker obese-diabetic rat by rosuvastatin-altered RhoA/Rho-kinase signaling.

Authors:  Christopher J Wingard; Fatiha Moukdar; Raju Y Prasad; Brook L Cathey; Lois Wilkinson
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

5.  Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?

Authors:  Maureen E Mays; Carlos A Dujovne
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

Review 6.  Effects of atorvastatin on the different phases of atherogenesis.

Authors:  Paolo Rubba
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition.

Authors:  Ian Leonard Phillip Beales; Abigail Hensley; Yoon Loke
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-08-06

8.  Fluvastatin attenuated the effect of expression of β1 integrin in PAN-treated podocytes by inhibiting reactive oxygen species.

Authors:  Jia Liu; Bo Zhang; Yuping Chai; Yaguang Xu; Changying Xing; Xiaoyun Wang
Journal:  Mol Cell Biochem       Date:  2014-09-21       Impact factor: 3.396

9.  Atorvastatin protects against cerebral ischemia/reperfusion injury through anti-inflammatory and antioxidant effects.

Authors:  Qiuyun Tu; Hui Cao; Wei Zhong; Binrong Ding; Xiangqi Tang
Journal:  Neural Regen Res       Date:  2014-02-01       Impact factor: 5.135

Review 10.  Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?

Authors:  Siu Wai Choi; Cyrus K Ho
Journal:  Redox Rep       Date:  2017-05-17       Impact factor: 4.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.